Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03997370 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
A Phase 1 study of Malignant Solid Neoplasm, sponsored by NRG Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT03997370: Recruiting Phase 1 study of Malignant Solid Neoplasm, sponsored by NRG Oncology.
NCT03997370 is a Phase 1 study of Malignant Solid Neoplasm that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 350 participants, below the 1,139-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03997370, a Phase 1 study of Malignant Solid Neoplasm, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Primary Outcome
Will be quantified by the median percentage error (PE), root-mean-squared error (RMSE), interquartile range (IQR) of the residuals, and median absolute percentage error (APE). In addition, the percentage of patients for which the observed carboplatin AUC is within 17% of target will be calculated. The actual AUC will be quantified using atomic absorption spectrophotometry.
Conditions Studied
Interventions
- DRUG Carboplatin
- PROCEDURE Biospecimen Collection
- DRUG Iohexol
Study Locations (20)
Colorado
- UCHealth University of Colorado Hospital - Aurora
- Poudre Valley Hospital - Fort Collins
- Cancer Care and Hematology-Fort Collins - Fort Collins
- UCHealth Greeley Hospital - Greeley
- Medical Center of the Rockies - Loveland
California
- UC San Diego Health System - Encinitas - Encinitas
- UC San Diego Moores Cancer Center - La Jolla
- University of California Davis Comprehensive Cancer Center - Sacramento
- UC San Diego Medical Center - Hillcrest - San Diego
Arizona
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CARTI Cancer Center - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Hartford Hospital - Hartford
- The Hospital of Central Connecticut - New Britain
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2028-02-06 |
| Phase | Phase 1 |
What NCT03997370 shows while recruiting
NCT03997370 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 1,139-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT03997370 names 20 study sites across 7 states, led by Colorado, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03997370 about?
NCT03997370 is a clinical study titled "Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol". This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by ...
What is the current status of trial NCT03997370?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2020-01-15. Estimated completion is 2028-02-06.
What conditions does trial NCT03997370 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm.
What interventions are being tested in trial NCT03997370?
The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Iohexol (DRUG).
Who is sponsoring clinical trial NCT03997370?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03997370 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03997370's enrollment target sits among peer trials
350 44th of 176 higher than 132 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
-
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT04042259 · 350 participants · NA
Delayed Primary Closure Using Negative Pressure Wound Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI